Its cardioprotective effect is independent of the presence of T2DM (163)
In the large retrospective study of 461,382 GLP-1 users, vitamin D deficiency was diagnosed in 7.5% at six months and 13.6% at twelve months
Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: A randomised, double-blind, placebo-controlled trial
The retatrutide-treated diabetic group showed intermediate results, although the authors noted that the treatment did not produce statistically robust protection under the study conditions
In this article, the term refers to dosing strategies below the initiation levels used in large clinical trials (see Key Definitions below)
Key readouts include: TRIUMPH-1 (obesity): Participants on the 12 mg weekly dose achieved an average body-weight reduction of roughly 28.3% at 80 weeks and up to 30.3% at 104 weeks , figures that approach outcomes previously associated only with bariatric surgery